Skip to main content
. Author manuscript; available in PMC: 2019 Jun 30.
Published in final edited form as: Infect Genet Evol. 2018 Oct 25;67:23–32. doi: 10.1016/j.meegid.2018.10.018

Table 4.

Tigecycline Minimal Inhibitory Concentrations (MICs) in the absence and presence of efflux pump inhibitors.

Strain TGC TGC + CCCP TGC + RES TGC + VER
(mg/L)
VRE57 0.060 0.060 0.060 0.030
VRE65 1.000 1.000 1.000 0.250
VRE69 1.000 1.000 1.000 0.250
VRE80 1.000 1.000 1.000 0.250
VRE109 0.060 0.030 0.060 0.030
A1 0.060 0.030 0.060 0.030
A11 0.125 0.125 0.125 0.030
A20 0.500 0.500 0.500 0.060
A42 1.000 1.000 1.000 0.125
B1 0.060 0.060 0.060 0.030
B21 0.250 0.250 0.250 0.030
B42 0.500 0.500 0.500 0.125
C1 0.060 0.030 0.060 0.030
C6 0.125 0.125 0.125 0.06
C42 1.000 1.000 0.500 0.125
VRE109(pAT28) 0.060 N/A N/A N/A
VRE109(pAT28-hypVRE80) 0.125 N/A N/A N/A
VRE109(pAT28-rpsJVRE80) 0.060 N/A N/A N/A
OG1RF(pMSP3535) 0.060 N/A N/A N/A
OG1RF(pMSP3535-abcVRE80) 0.060 N/A N/A N/A
VRE109(pAT28-marR VRE109) 0.060 N/A N/A N/A
VRE109(pAT28-marRB42) 0.125 N/A N/A N/A
B42(pAT28) 1.000 N/A N/A N/A
B42(pAT28-marRVRE109) 1.000 N/A N/A N/A
B42(pAT28-marRB42) 2.000 N/A N/A N/A

TGC: tigecycline; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; RES: reserpine; VER: verapamil; N/A: not applicable.